<?xml version="1.0" encoding="UTF-8"?>
<p>As its pathogenesis is uncertain, there is no existing consensus as to how chronic chikungunya arthritis (CCA) should be treated. In addition to symptomatic treatment with NSAIDs, a variety of inflammation suppressing therapies, including corticosteroids, chloroquine (CHQ), hydroxychloroquine (HCQ), sulfasalazine (SSZ), methotrexate (MTX), and immune-modulating biologic agents including anti-TNF agents, B-lymphocyte depletion (rituximab), and interleukin-6 receptor inhibition (tocilizumab), have been used [
 <xref rid="B13-viruses-11-00289" ref-type="bibr">13</xref>,
 <xref rid="B18-viruses-11-00289" ref-type="bibr">18</xref>,
 <xref rid="B19-viruses-11-00289" ref-type="bibr">19</xref>]. The treatment strategy has been empirical and no high-quality, controlled, randomized trials have assessed these interventions in CCA [
 <xref rid="B19-viruses-11-00289" ref-type="bibr">19</xref>].
</p>
